Biological E gets DCGI nod for phase 2/3 trials of its Covid vaccine on 5-18 year age group
The prospective, randomized, double-blind, placebo controlled, phase-2/3 trials of 'Corbevax' will be conducted across 10 sites in the country
The prospective, randomized, double-blind, placebo controlled, phase-2/3 trials of 'Corbevax' will be conducted across 10 sites in the country